GUD:CA:TSX-Knight Therapeutics Inc. (CAD)

EQUITY | Drug Manufacturers - Specialty & Generic | Toronto Stock Exchange

Last Closing

CAD 5.75

Change

+0.05 (+0.88)%

Market Cap

CAD 1.31B

Volume

0.07M

Analyst Target

CAD 8.74
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Knight Therapeutics Inc is a specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-28 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
BHC:CA Bausch Health Companies Inc

-0.18 (-1.64%)

CAD 4.27B
TLRY:CA Tilray Inc

-0.06 (-3.80%)

CAD 1.89B
CURA:CA Curaleaf Holdings Inc.

-0.01 (-0.55%)

CAD 1.61B
CRON:CA Cronos Group Inc

-0.01 (-0.37%)

CAD 1.08B
DHT-UN:CA DRI Healthcare Trust

-0.11 (-0.93%)

CAD 0.75B
AOV:CA Amotiv Limited

N/A

CAD 0.58B
DHT-U:CA DRI Healthcare Trust

N/A

CAD 0.54B
WEED:CA Canopy Growth Corp

-0.11 (-3.64%)

CAD 0.47B
ACB:CA Aurora Cannabis Inc

-0.07 (-1.30%)

CAD 0.36B
CPH:CA Cipher Pharmaceuticals Inc

+0.29 (+2.11%)

CAD 0.36B

ETFs Containing GUD:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.68% 78% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.68% 78% C+ 90% A-
Trailing 12 Months  
Capital Gain 6.28% 81% B- 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.28% 81% B- 28% F
Trailing 5 Years  
Capital Gain -26.56% 86% B+ 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.56% 86% B+ 13% F
Average Annual (5 Year Horizon)  
Capital Gain -2.24% 59% D- 17% F
Dividend Return -2.24% 59% D- 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.66% 100% F 57% F
Risk Adjusted Return -15.25% 45% F 14% F
Market Capitalization 1.31B 78% C+ 61% D-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 74.10 53% 13%
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital 1.47% 74% 34%
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector